Transforming Lives with Cutting-Edge Technology

Medtronic’s Inceptiv system is poised to redefine the landscape of pain therapy, delivering unparalleled relief and enhancing patient quality of life. With advanced closed-loop technology, this device adapts in real-time to provide optimal stimulation based on individual needs, reducing discomfort and improving efficacy.

Pioneering Closed-Loop Technology for Enhanced Patient Outcomes

The introduction of Inceptiv marks a pivotal moment in the field of neuromodulation. Unlike traditional open-loop systems, which deliver a fixed level of stimulation, Inceptiv dynamically adjusts its output according to physiological signals from the body. This innovation significantly reduces the risk of overstimulation, a common issue that can lead to discomfort and suboptimal pain relief.

Clinical trials have shown remarkable results, with 93% of patients experiencing a reduction in overstimulation during in-clinic testing. Moreover, 88% of participants preferred having the closed-loop feature activated, underscoring the system's superior performance. These outcomes highlight the potential of Inceptiv to enhance patient satisfaction and adherence to treatment regimens.

Long-Term Efficacy and Patient Satisfaction

The long-term benefits of Inceptiv are equally impressive. Data presented at the North American Neuromodulation Society 2025 meeting revealed that after 12 months, 91% of patients reported no uncomfortable stimulation during daily activities. Additionally, over four-fifths of participants experienced a 50% or greater improvement in low-back pain, a critical area of concern for many chronic pain sufferers.

A notable outcome was the reduction or cessation of opioid use among half of the patients. This shift towards non-pharmacological pain management underscores the transformative impact of Inceptiv on patient health and well-being. Furthermore, patients required minimal adjustments to the device's programming, making it user-friendly and efficient in everyday use.

Driving Market Growth and Competitive Advantage

Medtronic's success with Inceptiv has translated into robust market performance. Since its U.S. launch in April, the company has reported double-digit growth in pain stimulator sales, achieving increases of 11% and 10% in August and November, respectively. The neuromodulation business, which houses the pain stim unit, saw nearly 13% growth in Medtronic’s fiscal second quarter, ending in late October.

Analysts from Evercore ISI predict that Inceptiv will rejuvenate Medtronic's SCS business, helping the company regain lost market share from competitors like Abbott. By addressing key challenges such as overstimulation and user convenience, Inceptiv positions Medtronic as a leader in the rapidly evolving field of pain management technology.